Telix to Acquire ITM for US$1.65B, Creating a Radiopharmaceutical Powerhouse
TLX sits 80% above its 52-week low of $6.28.
Summary
Telix Pharmaceuticals announced a US$1.65B merger with ITM, the world's leading radioisotope supplier, adding a profitable manufacturing business and a Phase 3-completed therapeutic candidate while securing its supply chain.
Key Events · M&A and Partnerships · TLX
-
US$1.65B Merger with ITM Announced
Telix to acquire 100% of ITM Isotope Technologies Munich SE for US$1.65B upfront on a cash-free/debt-free basis, with ITM shareholders receiving approximately US$1.25B in Telix shares at US$11.84 per share.
-
Up to US$700M in Contingent Consideration
Additional payments tied to ITM-11 regulatory milestones: US$250M for FDA approvals across three indications through FY 2031, plus up to US$450M based on FY 2030 net global sales exceeding US$150M.
-
ITM-11 CRL Limited to CMC Issues
ITM-11 received a Complete Response Letter from the FDA on August 7, 2026 limited to Chemistry, Manufacturing and Controls and third-party facility items; no clinical safety or efficacy deficiencies were identified, and resubmission is a closing condition.
-
Combined Pro Forma Revenue Exceeds US$1.3B
Management estimates combined 2026 revenue and income exceeding US$1.3B, with ITM's manufacturing division expected to generate FY 2026 annualized EBITDA of US$106M and positive group EBITDA contribution from FY 2027.
Analysis · TLX · Life Sciences
Telix is acquiring ITM Isotope Technologies Munich SE, the world's leading supplier of therapeutic radioisotopes, for US$1.65 billion upfront plus up to US$700 million in contingent consideration. The deal is transformational: it adds a profitable, cash-generating isotope manufacturing business with US$273 million in 2025 revenue, secures Telix's supply chain for lutetium-177, and brings ITM-11, a Phase 3-completed therapeutic candidate for GEP-NETs that could accelerate Telix's entry into the commercial therapeutic market. ITM shareholders will own 23.7% of the combined company, representing significant dilution to existing holders, but the strategic rationale is clear — vertical integration across development, isotope production, and global manufacturing. The transaction is subject to Telix shareholder approval at an EGM expected in November 2026, with closing targeted by end of FY 2026. A key risk is ITM-11's regulatory status: it received a CRL from the FDA on August 7, 2026 limited to CMC and third-party facility items, with no clinical deficiencies identified, and resubmission is a closing condition.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 45% of the 300 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $11.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $6.28 to $13.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.